Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Federspiel, Jerome J., Lauren E. Wein, Kateena L. Addae-Konadu, Kristin C. Darwin, Laura E. Talamo, Evan R. Myers, and Andra H. James. “Venous thromboembolism incidence among patients recommended for pharmacologic thromboembolism prophylaxis after cesarean delivery in selected guidelines.” Journal of Thrombosis and Haemostasis : Jth, December 21, 2020. https://doi.org/10.1111/jth.15218.
PMID
33345404
Ridker, Paul M., Thomas L. Ortel, and Judith S. Hochman. “Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID.” Circulation 142, no. 24 (December 15, 2020): 2296–98. https://doi.org/10.1161/CIRCULATIONAHA.120.052069.
PMID
33054374
Daughety, Molly M., Andrew Morgan, Erin Frost, Chester Kao, Joyce Hwang, Rachel Tobin, Bhavik Patel, Matthew Fuller, Ian Welsby, and Thomas L. Ortel. “COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.” Thromb Res 196 (December 2020): 483–85. https://doi.org/10.1016/j.thromres.2020.10.004.
PMID
33091700
Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.” Kidney Int 98, no. 6 (December 2020): 1621. https://doi.org/10.1016/j.kint.2020.11.001.
PMID
33276869
Ridker, Paul M., Thomas L. Ortel, and Judith S. Hochman. “Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID.” Circulation 142, no. 24 (December 2020): 2296–98. https://doi.org/10.1161/circulationaha.120.052069.
PMID
33054374
Ridker, Paul M., Thomas L. Ortel, and Judith S. Hochman. “Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID.” Circulation 142, no. 24 (December 2020): 2296–98. https://doi.org/10.1161/circulationaha.120.052069.
PMID
33054374
Haykal, Tarek, Soheir Adam, and Thomas L. Ortel. “Meta-analysis fever in the wake of CARAVAGGIO.” Thromb Res 196 (December 2020): 141–42. https://doi.org/10.1016/j.thromres.2020.08.036.
PMID
32871305
Ahmadzia, Homa K., Naomi L. C. Luban, Shuhui Li, Dong Guo, Adam Miszta, Jogarao V. S. Gobburu, Jeffrey S. Berger, Andra H. James, Alisa S. Wolberg, and John van den Anker. “Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.” American Journal of Obstetrics and Gynecology, November 26, 2020. https://doi.org/10.1016/j.ajog.2020.11.035.
PMID
33248975
Ahmadzia, Homa K., Naomi L. C. Luban, Shuhui Li, Dong Guo, Adam Miszta, Jogarao V. S. Gobburu, Jeffrey S. Berger, Andra H. James, Alisa S. Wolberg, and John van den Anker. “Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.” Am J Obstet Gynecol, November 26, 2020. https://doi.org/10.1016/j.ajog.2020.11.035.
PMID
33248975
Oyedeji, Charity I., Tolulpe Oyesanya, Nathan Gray, and John J. Strouse. “Barriers and Facilitators of Advance Care Planning for Older Adults with Sickle Cell Disease.” In Blood, 136:58–59. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-136231.